OTC Allegra Filing Possibility Prepared For By Aventis – CEO
This article was originally published in The Tan Sheet
Executive Summary
Aventis recognizes and is preparing for the possibility that consumer healthcare companies might submit applications with FDA to market OTC versions of the low-sedating antihistamine Allegra
You may also be interested in...
FDA Rx-To-OTC Switch Petition Refusal Would Not Result In WellPoint Suit
WellPoint Health Networks will not sue FDA if the agency chooses to reject the health insurer's petitions on forcing Rx low- and non-sedating antihistamines to over-the-counter status
FDA Rx-To-OTC Switch Petition Refusal Would Not Result In WellPoint Suit
WellPoint Health Networks will not sue FDA if the agency chooses to reject the health insurer's petitions on forcing Rx low- and non-sedating antihistamines to over-the-counter status
FDA Rx-To-OTC Switch Petition Refusal Would Not Result In WellPoint Suit
WellPoint Health Networks will not sue FDA if the agency chooses to reject the health insurer's petitions on forcing Rx low- and non-sedating antihistamines to over-the-counter status